Chemotherapy Induced Nausea and Vomiting Prophylaxis in High-Dose Melphalan and Autologous Stem Cell Transplantation

We have read with great interest the paper by Trifilio S. and colleagues1, entitled “Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study”. The authors illustrated the result of a retrospective comparative clinical trial of olanzapine-contain ing regimen versus aprepitant or fosaprepitant-containing regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) among patients affected by multiple myeloma undergoing autologous stem cell transplantation (ASCT) with high dose melphalan (HDMel).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research